Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Matrix metalloproteinase inhibitors.

Nithya Ramnath1, Patrick J Creaven

  • 1Department of Medicine, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA.

Current Oncology Reports
|January 31, 2004
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Heterogeneous survival impact of immune-related adverse events in US veterans.

Journal for immunotherapy of cancer·2026
Same author

Maintenance Pemetrexed/Pembrolizumab Versus Pembrolizumab in Non-Small Cell Lung Cancer: A Propensity Score-Weighted Analysis.

JCO oncology practice·2026
Same author

Morning versus afternoon administration of immune checkpoint inhibitors in metastatic non-small-cell lung cancer.

Journal for immunotherapy of cancer·2026
Same author

HSR26-255: Impact of Immune-Related Adverse Events on Overall Survival Among U.S. Veterans: A Large Nationwide Cohort Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

HSR26-255: Impact of Immune-Related Adverse Events on Overall Survival Among U.S. Veterans: A Large Nationwide Cohort Analysis.

Journal of the National Comprehensive Cancer Network : JNCCN·2026
Same author

Brief Report: Real-World Outcomes of Lurbinectedin in Veterans With Small Cell Lung Cancer.

Clinical lung cancer·2026

Matrix metalloproteinases (MMPs) are key in cancer progression. While MMP inhibitors show promise, clinical trials have had mixed results, necessitating further research into their therapeutic potential.

Area of Science:

  • Biochemistry
  • Oncology
  • Pharmacology

Background:

  • Matrix metalloproteinases (MMPs) are enzymes crucial for extracellular matrix degradation.
  • MMPs play a significant role in tumor invasion, metastasis, and regulating cellular functions.
  • Dysregulation of MMPs is implicated in various pathological conditions, including cancer.

Purpose of the Study:

  • To review the current status of matrix metalloproteinase inhibitors (MMPIs) in cancer therapy.
  • To discuss the challenges and potential reasons for the limited success of MMPI clinical trials.
  • To highlight specific examples of MMPIs with positive outcomes in certain cancers.

Main Methods:

  • Literature review of preclinical and clinical studies on MMPs and MMPIs.
  • Analysis of factors contributing to the efficacy and limitations of MMPIs.

Related Experiment Videos

  • Examination of case studies involving marimastat and metastat.

    • Main Results:

    • MMPs are involved in tumor invasion and metastasis by degrading the extracellular matrix.
    • Most clinical trials of broad-spectrum MMP inhibitors have yielded disappointing results.
    • Selective MMPIs have shown positive outcomes in specific cancers like gastric cancer and Kaposi's sarcoma.

    Conclusions:

    • Targeting MMPs remains a complex therapeutic strategy due to their diverse roles.
    • Lack of selectivity and inappropriate trial design may explain the limited success of MMPIs.
    • Further research is needed to optimize MMPIs for effective cancer treatment.